Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7471.092 | 0.0009 | -1.0000 | 0.3860 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7472.092 | 0.8733 | 0.7973 | 1.2676 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7472.092 | 1.3877 | 1.5898 | 1.2676 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7472.092 | 0.8874 | 0.8201 | 1.2676 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7472.092 | 1.1136 | 1.1772 | 1.2676 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7472.092 | 1.1240 | 1.1933 | 1.2676 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7472.092 | 1.6382 | 1.9522 | 1.2676 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7472.092 | 2.3318 | 2.9002 | 1.2676 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7472.092 | 0.0007 | -0.9934 | 1.2676 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7472.092 | 0.0007 | -0.9934 | 1.2676 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7473.091 | 1.1494 | 1.1232 | 2.3297 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7473.091 | 1.4758 | 1.3637 | 2.3297 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7473.091 | 1.1196 | 1.0994 | 2.3297 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7473.091 | 1.0813 | 1.0683 | 2.3297 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7473.091 | 1.5006 | 1.3806 | 2.3297 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7473.091 | 1.0773 | 1.0650 | 2.3297 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7473.091 | 2.2915 | 1.8550 | 2.3297 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7473.091 | 0.0017 | -0.8711 | 2.3297 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7473.091 | 0.0006 | -0.9154 | 2.3297 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7474.09 | 1.2080 | 1.1610 | 2.4405 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7474.09 | 1.0599 | 1.0483 | 2.4405 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7474.09 | 1.1752 | 1.1368 | 2.4405 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7474.09 | 1.0183 | 1.0149 | 2.4405 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7474.09 | 1.1392 | 1.1097 | 2.4405 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7474.09 | 1.3394 | 1.2544 | 2.4405 |